Cellular immunity in allograft rejection: role of lymphocyte subpopulations and T-cell subsets in rat cardiac allograft rejection

Cellular Immunology
S F OluwoleM A Hardy

Abstract

In this study, cellular requirements for rejection are examined by the use of adoptive transfer assays in the ACI to Lewis cardiac allograft model. The findings show that adoptive transfer of 1 x 10(8) spleen cells (SpL), 5 x 10(7) T-cells, and 2 x 10(7) helper T-cells (W3/25+) obtained from normal, nonsensitized donors restores acute ACI graft rejection in sublethally irradiated (750 rad) Lewis recipients. In contrast, reconstitution with 2 x 10(7) cytotoxic T-cells (0X8+) does not restore first-set graft rejection. Reconstitution of the irradiated recipients with either W3/25+ or 0X8+ T-cells obtained from specifically sensitized syngeneic donors resulted in acute rejection. The W3/25+ T-cell subset was significantly more potent (P less than 0.01) in effecting rejection on a per-cell basis. Adoptive transfer of SpL, T-cells, and 0X8+ T-cells obtained from sensitized rats led to accelerated cardiac allograft rejection in the naive secondary recipients while W3/25+ T-cells did not. This study suggests that although the W3/25+ T-cells alone have the capacity to initiate first-set graft rejection, both W3/25+ and 0X8+ subsets appear to be critical to the completion of rejection of heart allografts. We also examined the capacity o...Continue Reading

References

Sep 1, 1988·Transplantation·A FarnsworthS E Dorsch
May 1, 1986·Transplantation·S Cobbold, H Waldmann
Dec 1, 1982·Transplantation Proceedings·R P LowryR D Forbes
May 1, 1980·Transplantation·A E Chang, P H Sugarbaker
Dec 15, 1954·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·R E BILLINGHAMP B MEDAWAR

❮ Previous
Next ❯

Citations

May 23, 2002·Transplantation·Christian S KuhrRainer Storb
Sep 18, 2015·Microbial Cell Factories·Stephanie Galanie, Christina D Smolke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
M P ColomboP J Wettstein
Proceedings of the National Academy of Sciences of the United States of America
D E SpeiserR M Zinkernagel
© 2022 Meta ULC. All rights reserved